Glenmark Generics, a subsidiary of pharmaceutical firm Glenmark has received abbreviated new drug application (ANDA) approval from US Food and Drug Administration (US FDA) for Trandolapril tablets and will immediately commence marketing and distribution of these products in the US market.


</p><tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>Trandolapril is an&nbsp; ACE (angiotensin converting enzyme) inhibitor used to treat high blood pressure and is the generic equivalent of Mavik tablets marketed by Abott Laboratories. The total sales for Trandolapril tablets in the 12 month period ending March, 2008 were in excess of $23 million as per IMS Health.</P></p><p class='TableClas'></p></table>


Glenmark gets USFDA approval for Trandolapril

Also Read

Great Off-shore bags order for $ 15 million

NTPC's 500 mw Sipat unit commences operation

Advanta buys sunflower business of Limagrain in US

IOC must supply diesel at lower price: Lanka

Indian-owned Tamarai is best late night bar in UK

Explore News